Results 161 to 170 of about 26,508 (195)

Probing inclusion complexes of 2-hydroxypropyl-β-cyclodextrin with mono-amino mono-carboxylic acids: physicochemical specification, characterization and molecular modeling. [PDF]

Heliyon, 2020
Esmaeilpour D, Hussein AA, Almalki FA, Shityakov S, Bordbar AK.   +4 more
europepmc   +1 more source

2-Hydroxypropyl-β-cyclodextrin Ototoxicity in Adult Rats: Rapid Onset and Massive Destruction of Both Inner and Outer Hair Cells Above a Critical Dose. [PDF]

Neurotox Res, 2020
Liu X, Ding D, Chen GD, Li L, Jiang H, Salvi R.   +5 more
europepmc   +1 more source

The NK1 antagonist L822429 inhibits stress-induced reinstatement of alcohol seeking behavior in rats [PDF]

, 2010
Cheng, Kejun, Heilig, Markus, Rice, Kenner C, Rowe, Kelly E, Schank, Jesse R, Thorsell, Annika   +5 more
core   +1 more source

Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.

Current Topics in Medicinal Chemistry, 2014
E. Ottinger, Mark L. Kao, Nuria Carrillo-Carrasco, N. Yanjanin, R. Shankar, M. Janssen, M. Brewster, I. Scott, Xin Xu, J. Cradock, P. Terse, S. Dehdashti, J. Marugan, Wei Zheng, Lili M. Portilla, A. Hubbs, W. Pavan, John D Heiss, C. Vite, S. Walkley, D. Ory, S. Silber, F. Porter, C. Austin, J. McKew   +24 more
semanticscholar   +1 more source

2-Hydroxypropyl-β-Cyclodextrin Aggregates: Identification and Development of Analytical Techniques. [PDF]

Materials (Basel), 2018
Sá Couto AR, Ryzhakov A, Loftsson T.
europepmc   +1 more source

2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease. [PDF]

Biochim Biophys Acta Mol Cell Biol Lipids, 2019
Davidson J, Molitor E, Moores S, Gale SE, Subramanian K, Jiang X, Sidhu R, Kell P, Zhang J, Fujiwara H, Davidson C, Helquist P, Melancon BJ, Grigalunas M, Liu G, Salahi F, Wiest O, Xu X, Porter FD, Pipalia NH, Cruz DL, Holson EB, Schaffer JE, Walkley SU, Maxfield FR, Ory DS.   +25 more
europepmc   +1 more source

Designing a Formulation of the Nootropic Drug Aniracetam Using 2-Hydroxypropyl-β-Cyclodextrin Suitable for Parenteral Administration. [PDF]

Pharmaceutics, 2018
Goldsmith SD, McDowell A.
europepmc   +1 more source

BIOAVAILABILITY ENHANCEMENT OF POORLY WATER SOLUBLE DRUGS [PDF]

, 2020
GIANNINO, VALENTINA
core  

Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin. [PDF]

Mol Genet Metab, 2018
Cougnoux A, Clifford S, Salman A, Ng SL, Bertin J, Porter FD.   +5 more
europepmc   +1 more source